Table 1

Baseline data

Intervention group (n=47)Control group (n=42)
Age (years)10.4 (2.9)10.2 (2.9)
Sex male28 (60%)22 (52%)
ACQ2.5 (0.8)2.3 (0.7)
FEV1%87.2 (14.9)88.0 (13.4)
PQL4.3 (1.5)4.6 (1.2)
ICS dose697.9 (348.6)664.3 (280.1)
BTS3.5 (0.6)3.4 (0.5)
Proportion BTS ≥451%43%
GP/ED visits1.9 (2.2)2.1 (2.0)
β-Agonist2.5 (1.3)2.3 (1.3)
School days missed3.5 (4.4)3.8 (5.7)
Oral steroids1.2 (1.8)1.2 (1.3)
Hospital admissions0.3 (0.6)0.2 (0.6)
BMQ score2.5 (0.5)2.6 (0.4)
IPQ score5.6 (1.3)5.3 (0.9)
Ethnicity WB30 (64%)24 (57%)
 BA3 (6%)6 (14%)
 BP11 (23%)11 (26%)
 BI0 (0%)1 (2%)
 AO1 (2%)0 (%)
 BC2 (4%)0 (%)
Time from asthma diagnosis (years)6.0 (3.7)6.7 (3.7)
  • Data are mean (SD) or n (%).

  • Calculations subject to rounding errors.

  • GP/ED visits, school days missed, oral steroids required and hospital admissions are all parent-reported events over the previous 3 months.

  • ACQ, Asthma Control Questionnaire; AO, Asian other; BA, black African; BC, black Caribbean; β-agonist use—score on ACQ question; BI, British Indian; BMQ, Beliefs about Medicines Questionnaire; BP, British Pakistani; BTS, British Thoracic Society; FEV1%, FEV1% predicted; ICS dose, inhaled corticosteroid dose (beclomethasone equivalent); IPQ, Illness Perceptions Questionnaire; PQL, Paediatric Quality of Life Questionnaire; WB, white British.